ReviewCancers2021
Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.International journal of molecular sciences · 2025Review
- Flavonoids and Flavonoid-Based Nanopharmaceuticals as Promising Therapeutic Strategies for Colorectal Cancer-An Updated Literature Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Anticancer Potential of Pineapple and its Bioactive Compound Bromelain.Current pharmaceutical design · 2025Review
- An ellagitannin-loaded CS-PEG decorated PLGA nano-prototype promotes cell cycle arrest in colorectal cancer cells.Cell biochemistry and biophysics · 2023Article
- Novel Antitumor Agents Based on Fluorescent Benzofurazan Derivatives and Mesoporous Silica.International journal of molecular sciences · 2022Article
- Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments.Neoplasia (New York, N.Y.) · 2022Review
- Basal Cell Carcinoma: Pathology, Current Clinical Treatment, and Potential Use of Lipid Nanoparticles.Cancers · 2022Review
- Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy.Frontiers in pharmacology · 2022Review
- Chemical Conjugation in Drug Delivery Systems.Frontiers in chemistry · 2022Review
- Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis.Frontiers in pharmacology · 2022Article
- Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research.Pharmaceutics · 2021Review
- Size- and Surface- Dual Engineered Small Polyplexes for Efficiently Targeting Delivery of siRNA.Molecules (Basel, Switzerland) · 2021Article
- Liposomal nanotherapeutics for cancer treatment: Targeted delivery and immunotherapy.International journal of immunopathology and pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Physicochemical, pharmacokinetic, and biopharmaceutical characterization tools play a key role in the assessment of nanopharmaceuticals' potential imaging analysis and for site-specific delivery of anti-cancers to neoplastic cells/tissues. If diagnostic tools and therapeutic approaches are combined in one single nanoparticle, a new platform called nanotheragnostics is generated. Several analytical technologies allow us to characterize nanopharmaceuticals and nanoparticles and their properties so that they can be properly used in cancer therapy. This paper describes the role of multifunctional nanoparticles in cancer diagnosis and treatment, describing how nanotheragnostics can be useful in modern chemotherapy, and finally, the challenges associated with the commercialization of nanoparticles for cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.